Table 2.
Table 2a. cg25713625 (STEAP3) | |||||||
---|---|---|---|---|---|---|---|
Base model, polynomial order 010, Fig. 2a | |||||||
Group 2 (intermediate) vs. group 1 (low) | Group 3 (high) vs. group 1 (low) | ||||||
Outcome | OR | 95% CI | p c | OR | 95% CI | p c | Global pd |
CV | 0.662 | 0.21 to 2.03 | 0.471 | 1.126 | 0.33 to 3.80 | 0.847 | 0.351 |
DCI | 1.032 | 0.45 to 2.41 | 0.941 | 1.256 | 0.49 to 3.20 | 0.629 | 0.789 |
GOS-3 | 2.982 | 0.86 to 12.56 | 0.1 | 11.743 | 3.14 to 21.65 | 0.0006 a | 0.00005 a |
GOS-12 | 6.346 | 1.47 to 31.32 | 0.029 b | 15.595 | 3.35 to 22.54 | 0.0018 a | 0.0005 a |
Death-3 | 7.147 | 1.00 to 32.53 | 0.076 | 19.081 | 3.01 to 25.12 | 0.0093 b | 0.0013 a |
Death-12 | 4.859 | 1.00 to 35.80 | 0.064 | 12.762 | 2.71 to 25.13 | 0.0041 b | 0.0015 a |
CTH-adjusted model, polynomial order 000, Fig. 2b | |||||||
Group 2 (intermediate) vs. group 1 (low) | Group 3 (high) vs. group 1 (low) | ||||||
Outcome | OR | 95% CI | p c | OR | 95% CI | p c | Global pd |
CV | 0.433 | 0.14 to 1.26 | 0.131 | 0.832 | 0.25 to 2.70 | 0.76 | 0.129 |
DCI | 0.612 | 0.27 to 1.36 | 0.231 | 0.913 | 0.37 to 2.20 | 0.84 | 0.260 |
GOS-3 | 2.589 | 0.80 to 9.35 | 0.115 | 4.143 | 1.25 to 5.01 | 0.0271 b | 0.062 |
GOS-12 | 3.960 | 1.00 to 10.58 | 0.055 | 5.972 | 1.52 to 6.25 | 0.0182 b | 0.0326 b |
Death-3 | 3.768 | 0.90 to 11.54 | 0.108 | 4.847 | 1.05 to 7.50 | 0.069 | 0.122 |
Death-12 | 3.120 | 0.86 to 15.63 | 0.115 | 4.249 | 1.06 to 5.25 | 0.059 | 0.123 |
Table 2b. cg08866780 (APP) | |||||||
Base model, polynomial order 000, Fig. 2d | |||||||
Group 2 (intermediate) vs. group 1 (low) | Group 3 (high) vs. group 1 (low) | ||||||
Outcome | OR | 95% CI | p c | OR | 95% CI | p c | Global pd |
CV | 0.443 | 0.19 to 0.989 | 0.051 | 0.366 | 0.14 to 1.00 | 0.056 | 0.069 |
DCI | 0.803 | 0.44 to 1.48 | 0.479 | 1.156 | 0.56 to 2.41 | 0.698 | 0.488 |
GOS-3 | 0.349 | 0.16 to 0.74 | 0.0060 b | 0.760 | 0.32 to 1.82 | 0.541 | 0.0118 b |
GOS-12 | 0.194 | 0.08 to 0.44 | 0.0001 a | 0.826 | 0.39 to 1.98 | 0.672 | 0.0001 a |
Death-3 | 0.209 | 0.08 to 0.52 | 0.0010 a | 1.080 | 0.44 to 2.67 | 0.868 | 0.0002 a |
Death-12 | 0.206 | 0.08 to 0.50 | 0.0006 a | 0.977 | 0.39 to 2.43 | 0.96 | 0.0002 a |
CTH-adjusted model, polynomial order 000, Fig. 2e | |||||||
Group 2 (intermediate) vs. group 1 (low) | Group 3 (high) vs. group 1 (low) | ||||||
Outcome | OR | 95% CI | p c | OR | 95% CI | p c | Global pd |
CV | 0.813 | 0.37 to 1.76 | 0.602 | 0.654 | 0.25 to 1.67 | 0.374 | 0.672 |
DCI | 1.230 | 0.68 to 2.24 | 0.494 | 1.400 | 0.67 to 2.97 | 0.377 | 0.656 |
GOS-3 | 0.332 | 0.16 to 0.70 | 0.0040 b | 0.683 | 0.27 to 1.67 | 0.4072 | 0.0097 b |
GOS-12 | 0.347 | 0.15 to 0.77 | 0.0097 b | 1.070 | 0.43 to 2.68 | 0.8853 | 0.0066 b |
Death-3 | 0.359 | 0.15 to 0.87 | 0.0237 b | 1.284 | 0.50 to 3.31 | 0.6028 | 0.0091 b |
Death-12 | 0.337 | 0.14 to 0.79 | 0.0128 b | 1.143 | 0.44 to 2.95 | 0.7817 | 0.0072 b |
Table 2c. cg08553327 (TNF) | |||||||
Base model, polynomial order 212, Fig. 2g | |||||||
Group 2 (intermediate) vs. group 1 (low) | Group 3 (high) vs. group 1 (low) | ||||||
Outcome | OR | 95% CI | p c | OR | 95% CI | p c | Global pd |
CV | 0.850 | 0.42 to 1.72 | 0.651 | 1.223 | 0.31 to 5.36 | 0.777 | 0.844 |
DCI | 0.827 | 0.47 to 1.46 | 0.516 | 3.066 | 0.98 to 11.64 | 0.069 | 0.101 |
GOS-3 | 3.686 | 1.78 to 7.87 | 0.0005 a | 13.134 | 3.51 to 39.02 | 0.0003 a | 0.00001 a |
GOS-12 | 2.080 | 0.98 to 4.43 | 0.0568 | 4.488 | 1.24 to 16.50 | 0.0209 b | 0.0244 b |
Death-3 | 2.488 | 1.11 to 5.57 | 0.0257 b | 5.603 | 1.47 to 20.44 | 0.0089 b | 0.0094 b |
Death-12 | 2.496 | 1.12 to 5.56 | 0.0243 b | 7.123 | 1.89 to 27.94 | 0.0037 b | 0.0038 b |
Corresponds to trajectory groups depictured in Fig. 2a (STEAP3), 2b (STEAP3 + CTH), 2d (APP), 2e (APP + CTH), and 2g (TNF). Base model, unadjusted for CTH; OR, odds ratio; CI, confidence interval; p, p-value based on an alpha of 0.05; Global p, p-value computed using partial F test comparing models with and without trajectory group; CTH, cell type heterogeneity; CV, cerebral vasospasm; DCI, delayed cerebral ischemia; GOS-3, Glasgow Outcome Scale at 3 months (unfavorable = 1–3); GOS-12, Glasgow Outcome Scale at 12 months (unfavorable = 1–3); Death-3, death at 3 months; Death-12, death at 12 months.
Significant associations (meeting empirical significance level) have been bolded.
Suggestive associations (unadjusted p < 0.05) have been underlined.
Empirical significance threshold = 0.002 (calculated based on the minimum of 12 p-values, including both group 2 vs. group 1 and group 3 vs. group 1 comparisons, in permutation testing).
Empirical significance threshold for global analysis = 0.003 (calculated based on the minimum of 6 p-values in permutation testing)